CLRB - CIK 0001279704
The table below shows Cellectar Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.85M | -$9.38M | -$13.36M | -$7.18M | -$5.04M | -$4.75M |
| Capital expenditure | $3.38K | - | $21.63K | - | $30.07K | - |
| Investing cash flow | -$3.38K | - | -$21.63K | - | -$30.07K | - |
| Dividends paid | - | - | - | - | - |
Cellectar Biosciences, Inc. reported operating cash flow of -$23.12M for fiscal year 2025. That is up 51.4% from -$47.58M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$8.28M (FY 2016) to -$23.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | - | $43.85M | $3.00 | - | $1.21M |